Comparing Collegium Pharmaceutical (COLL) & Teligent (NASDAQ:TLGT)
Collegium Pharmaceutical (NASDAQ: COLL) and Teligent (NASDAQ:TLGT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitabiliy and analyst recommendations.
Earnings and Valuation
This table compares Collegium Pharmaceutical and Teligent’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Collegium Pharmaceutical||$3.88 million||92.85||-$101.25 million||($3.99)||-3.07|
|Teligent||$71.12 million||6.69||$9.15 million||($0.19)||-47.05|
Teligent has higher revenue and earnings than Collegium Pharmaceutical. Teligent is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
82.3% of Collegium Pharmaceutical shares are held by institutional investors. Comparatively, 63.6% of Teligent shares are held by institutional investors. 25.8% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 22.6% of Teligent shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Collegium Pharmaceutical and Teligent’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings for Collegium Pharmaceutical and Teligent, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Collegium Pharmaceutical presently has a consensus target price of $24.00, indicating a potential upside of 96.24%. Teligent has a consensus target price of $10.00, indicating a potential upside of 11.86%. Given Collegium Pharmaceutical’s higher possible upside, research analysts plainly believe Collegium Pharmaceutical is more favorable than Teligent.
Volatility and Risk
Collegium Pharmaceutical has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500. Comparatively, Teligent has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Teligent, Inc. is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 34 Abbreviated New Drug Application(ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.